ORLANDO, Fla.—In adults with binge-eating disorder, the developmental drug dasotraline was linked with significant gains in behavioral and psychological outcomes compared with placebo. Researchers presented study findings during a poster session at Psych Congress 2018.
The double-blind trial randomized 317 patients with binge-eating disorder to 12 weeks of treatment with placebo or flexibly-dosed (4 mg/day, 6 mg/day, and 8 mg/day) dasotraline, a novel dual-acting dopamine and norepinephrine reuptake inhibitor.
From baseline through week 12, the mean drop in the number of binge-eating days per week was significantly greater with dasotraline, compared with placebo (-3.74 vs -2.75), according to the study.
Furthermore, dasotraline significantly outperformed placebo on mean endpoint changes on the Yale-Brown Obsessive-Compulsive Scale Modified for Binge Eating total score (-17.05 vs -9.88), obsession subscale score (-8.32 vs -4.58), and compulsion subscale score (-8.69 vs -5.35). On the Eating Disorder Examination Questionnaire Brief Version, the mean endpoint change was also significantly greater with dasotraline compared with placebo on the global score (-0.85 vs -0.23) as well as subscale scores measuring dietary restraint (-0.55 vs +0.15), shape concern (-0.93 vs -0.43), and weight concern (-1.03 vs -0.44).
Sunovion Pharmaceuticals Inc., the developer of dasotraline, sponsored the study. Researchers involved with the study were associated with Sunovion Pharmaceuticals; McLean Hospital, Belmont, Massachusetts; and the Lindner Center of HOPE, Mason, Ohio.
Navia B, Hudson JI, McElroy SL, et al. Dasotraline for treatment of adults with binge-eating disorder: effect on behavioral outcomes. Poster presented at Psych Congress 2018: October 25-28, 2018; Orlando, FL. Poster 311.